Wednesday, August 06, 2025 9:38:42 AM
Assuming 40 Mil per quarter in FY 2026
Elite Revenues (2019–2026)
Revenue scaled so 50 “#” = $160 M
2019 | ## ($ 7.57 M)
2020 | ###### ($17.99 M)
2021 | ######## ($25.38 M)
2022 | ########## ($32.26 M)
2023 | ########### ($34.16 M)
2024 | ################## ($56.63 M)
2025 | ##########################($84.04 M)
2026 | ################################################## ($160.00 M)
-------------
Assuming 50 Million per quarter:
2019 | ## ($ 7.57 M)
2020 | ##### ($ 17.99 M)
2021 | ###### ($ 25.38 M)
2022 | ######## ($ 32.26 M)
2023 | ######### ($ 34.16 M)
2024 | ############## ($ 56.63 M)
2025 | ##################### ($ 84.04 M)
2026 | ################################################## ($200.00 M)
Elite Revenues (2019–2026)
Revenue scaled so 50 “#” = $160 M
2019 | ## ($ 7.57 M)
2020 | ###### ($17.99 M)
2021 | ######## ($25.38 M)
2022 | ########## ($32.26 M)
2023 | ########### ($34.16 M)
2024 | ################## ($56.63 M)
2025 | ##########################($84.04 M)
2026 | ################################################## ($160.00 M)
-------------
Assuming 50 Million per quarter:
2019 | ## ($ 7.57 M)
2020 | ##### ($ 17.99 M)
2021 | ###### ($ 25.38 M)
2022 | ######## ($ 32.26 M)
2023 | ######### ($ 34.16 M)
2024 | ############## ($ 56.63 M)
2025 | ##################### ($ 84.04 M)
2026 | ################################################## ($200.00 M)
??7?? - I trust Nasrat Hakim to lead this company to a successful Buyout
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 11:00:24 AM
- Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product • Newsfile • 06/01/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
